Treatment of HER2+ breast cancer: a retrospective of disease prognosis with loss of HER2 amplification on residual disease after neoadjuvant treatment in a community hospital setting.

Uczkowski, Dariusz; Sekhri, Arunabh; Gupta, Shilpi; Gendler, Leah; Misiukiewicz, Krzysztof; Levin, Miles; Guerin, Bonni

Uczkowski, Dariusz; Sekhri, Arunabh; Gupta, Shilpi; Gendler, Leah; Misiukiewicz, Krzysztof; Levin, Miles; Guerin, Bonni.

Afiliação

Uczkowski D; Department of Internal Medicine, Overlook Medical Center Summit, New Jersey, USA.
Sekhri A; Department of Oncology, RWJ Barnabas Health, Jersey City Medical Center Jersey, New Jersey, USA.
Gupta S; Department of Oncology, Morristown Medical Center Morristown, New Jersey, USA.
Gendler L; Department of Oncology, Morristown Medical Center Morristown, New Jersey, USA.
Misiukiewicz K; Department of Oncology, Icahn School of Medicine at Mount Sinai New York, New York, USA.
Levin M; Department of Internal Medicine, Overlook Medical Center Summit, New Jersey, USA.
Guerin B; Department of Internal Medicine, Overlook Medical Center Summit, New Jersey, USA.

Am J Cancer Res ; 13(6): 2564-2571, 2023.

Article em En | MEDLINE | ID: mdl-37424818

Palavras-chave

HER2+; Targeted therapy; chemotherapy; hormone therapy; next-generation sequencing; triple positive

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Am J Cancer Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google